The Future of Basal Insulin Has Arrived ...

The approval of Awiqli (insulin icodec) by the U.S. Food and Drug Administration on March 26, 2026, marks a turning point in diabetes care. For the first time, patients have access to a once-weekly basal insulin, challenging the long-standing dominance of daily insulins like insulin glargine and insulin degludec.

This article provides a detailed, clinician-friendly comparison to help you understand where insulin icodec fits in modern diabetes management.

What Is Awiqli (Insulin Icodec)?

Awiqli is a once-weekly basal insulin analog designed to provide stable glucose control over 7 days with a single injection.

Key Features

• Once-weekly dosing
• FlexTouch pen (3 mL)
• 700 units/mL concentration
• Total 2100 units per pen
• Maximum 700 units per dose
• Dose increments: 10 units

Awiqli Dosing Made Simple

Insulin-Naïve Patients

• Start with 70 units once weekly

Patients Switching from Daily Insulin

Week 1 (Loading Phase)

Weekly Dose=1.5×(Daily Dose)×7\text{Weekly Dose} = 1.5 \times (\text{Daily Dose}) \times 7Weekly Dose=1.5×(Daily Dose)×7

• Round to nearest 10 units

Week 2 and Beyond

Weekly Dose=(Daily Dose)×7\text{Weekly Dose} = (\text{Daily Dose}) \times 7Weekly Dose=(Daily Dose)×7

This simple transition strategy ensures smooth pharmacokinetic adaptation.

Mechanism of Action: Similar Goal, Different Kinetics

All three insulins—icodec, glargine, and degludec—aim to:

• Maintain basal insulin levels
• Suppress hepatic glucose production
• Improve peripheral glucose uptake

However, their duration and stability differ significantly.

Head-to-Head Comparison

1. Dosing Frequency

👉 Awiqli dramatically reduces injection burden (52 vs 365 injections/year).

2. Duration of Action

• Degludec already improved flexibility
• Icodec takes it further with true weekly coverage

3. Pharmacokinetic Stability

• Glargine: stable but may show peakless variability
• Degludec: Ultra-stable, very low variability
• Icodec: Designed for flat, prolonged release over 7 days

👉 Early data suggests icodec may match degludec in stability, but with longer duration.

4. Dose Flexibility

👉 Degludec still offers more flexibility in timing, but icodec simplifies frequency.

5. Initiation and Titration

• Glargine & Degludec:
  • Start low
  • Titrate every few days
• Icodec:
  • Fixed starting dose (70 units weekly)
  • Weekly titration

👉 Icodec simplifies titration but requires careful early adjustment due to long half-life.

6. Hypoglycemia Risk

All basal insulins carry risk of hypoglycemia.

• Glargine: Moderate risk
• Degludec: Lower risk (especially nocturnal)
• Icodec: Comparable overall risk (based on current data)

👉 Long duration of icodec means:

• Hypoglycemia may last longer if it occurs
• Requires cautious dose escalation

7. Patient Adherence

This is where Awiqli stands out:

• Glargine: Missed doses are common
• Degludec: Improved adherence
• Icodec: Potentially highest adherence

👉 Ideal for:

• Busy patients
• Poor compliance
• Injection fatigue

Side Effects: Are They Different?

No major surprises here.

All three insulins share similar side effects:

• Hypoglycemia
• Weight gain
• Injection site reactions
• Lipodystrophy (rare)

👉 Awiqli does not introduce new safety concerns, but its long action requires vigilance.

When Should You Choose Awiqli?

Best Candidates

• Patients struggling with daily injections
• Those with poor adherence
• Type 2 diabetes needing basal insulin
• Patients preferring simplified regimens

Use With Caution

• Patients prone to frequent hypoglycemia
• Those requiring rapid dose adjustments
• Unstable or brittle diabetes

Clinical Perspective: Is Weekly Insulin the New Standard?

Not so fast.

While Awiqli is revolutionary, it will likely:

• Complement, not replace daily insulins
• Be preferred in selected patient populations
• Require real-world experience before widespread adoption

👉 Insulin degludec still remains the gold standard for flexibility and stability
👉 Insulin glargine remains widely used due to familiarity and cost

Final Thoughts

Awiqli (insulin icodec) represents a paradigm shift in diabetes care:

• From daily to weekly therapy
• From burden to simplicity
• From compliance issues to adherence solutions

However, like any powerful tool, it must be used wisely.

For clinicians focused on patient-centered care and long-term outcomes, Awiqli offers a compelling new option—especially for those who struggle with the demands of daily insulin therapy.